Information de reference pour ce titreAccession Number: | 00007885-200310000-00004.
|
Author: | Drew, W. Lawrence; Chou, Sunwen; Mohr, Beth A.; Assmann, Susan F.; Miner, Richard C.; Laycock, Megan E.; Busch, Michael P.; for the Viral Activation Transfusion Study Group
|
Institution: | University of California, San Francisco, California; Oregon Health Sciences University, Portland, Oregon; New England Research Institutes, Watertown, Massachusetts; Blood Centers of the Pacific, San Francisco, California; and Blood Systems, Inc., Scottsdale, Arizona.
|
Title: | |
Source: | Transfusion. 43(10):1351-1357, October 2003.
|
Abstract: | BACKGROUND: The Viral Activation Transfusion Study (VATS) afforded an opportunity to determine whether blood transfusions, and in particular exogenous WBCs, "activate" CMV replication in HIV-infected, CMV-seropositive patients, and whether such patients can be superinfected by additional strains of CMV transmitted via blood transfusions.
STUDY DESIGN AND METHODS: A total of 531 patients were randomized to receive either WBC-reduced (WBCR) or non-WBC-reduced (NWBCR) RBC units. Plasma CMV PCR assays were performed before transfusion and weekly after transfusion for 4 weeks. NWBCR cases with evidence of possible reactivation and/or superinfection were further studied for donor viremia by DNA PCR of frozen retention segments and new genotype acquisition using gB envelope sequence analysis of pre- and posttransfusion recipient specimens.
RESULTS: VATS patients received a median of two RBC units during their initial transfusion. Whether positive or negative for CMV DNA at baseline, there were no significant treatment-arm differences in the percentage of patients who had positive qualitative CMV PCR or increases in CMV viral load at follow-up. Of 50 recipients randomized to NWBCR RBC and meeting criteria for possible CMV superinfection, 25 had sufficient CMV DNA load in a baseline and one or more viremic follow-up sample to permit comparison of gB genotypes. Only two recipients showed genotype shifts. Of 125 WBC pellets prepared from the seropositive units transfused into these 50 cases, only 1 tested weakly PCR positive for CMV DNA (insufficient copy number for genotyping).
CONCLUSION: There was no evidence of "activation" of CMV by blood transfusion. Among the NWBCR RBC recipients, there was little evidence of possible transmission of new CMV strains. Hence, the current policy for transfusion support of HIV-infected patients, which allows transfusion of CMV-antibody-positive blood to CMV-seropositive patients, is appropriate.
(C) 2003 Blackwell Science Ltd.
|
References: | 1. Lang DJ. Cytomegalovirus infections in organ transplan-tation and post transfusion. An hypothesis. Archiv fur die gesamte Virusforschung. 1972;37:365-72.
2. Adler SP, Baggett J, McVoy M. Transfusion-associated cytomegalovirus infections in seropositive cardiac surgery patients. The Lancet 1985;2:743-7.
3. Drew WL, Mocarski ES, Sweet E, Miner RC. Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome: documentation by Southern blot hybridization. J Infect Dis 1984;150:952-3.
4. Spector SA, Hirata KK, Newman TR. Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis 1984;150:953-6.
5. Collier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001;285:1592-601.
6. Busch MP, Collier A, Gernsheimer T, et al. The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview. Transfusion 1996;36:854-9.
7. Yomtovian R, Gernsheimer T, Assmann SF, et al. Viral Activation Transfusion Study Group. WBC reduction in RBC concentrates by prestorage filtration: multicenter experience. Transfusion 2001;41:1030-6.
8. Long CM, Drew L, Miner R, et al. Detection of cytomegalovirus in plasma and cerebrospinal fluid specimens from human immunodeficiency virus-infected patients by the AMPLICOR CMV test. J Clin Microbiol 1998;36:2434-8.
9. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-603.
10. Chou S, Dennison KM. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 1991;163:1229-34.
11. Brecher ME, Triulzi DJ, Assmann SF. Number of RBC units and rate of transfusion to anemic HIV positive patients assigned to receive WBC-reduced or non-WBC-reduced RBCs: the viral activation transfusion study experience. Transfusion 2001;41:794-8.
12. Cheung KS, Lang DJ. Transmission and activation of cytomegalovirus with blood transfusion: a mouse model. J Infect Dis 1977;135:841-5.
13. Ho M. Epidemiology of cytomegalovirus infection in man. In: Greenough WB, Merigan TC, eds. Cytomegalovirus biology and infection: current topics in infectious disease. New York: Plenum Publishing, 1982: 79-104.
14. Chou S. Differentiation of cytomegalovirus strains by restriction analysis of DNA sequences amplified from clinical specimens. J Infect Dis 1990;162:738-42.
15. Chou S, Erice A, Jordan MC, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995;171:576-83.
16. Roback JD, Drew WL, Laycock ME, et al. Cytomegalovirus DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion 2003;43:314-21.
|
Language: | English.
|
Document Type: | TRANSFUSION PRACTICE.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0041-1132
|
NLM Journal Code: | wdn, 0417360
|
Annotation(s) | |
|
|